MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory…
MaaT PharmaMay 26, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaMay 3, 2023
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for…
MaaT PharmaApril 24, 2023
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting…
MaaT PharmaApril 11, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaApril 4, 2023
MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview As of December 31,…
MaaT PharmaMarch 30, 2023
MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications…
MaaT PharmaMarch 27, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaMarch 2, 2023
This press release is not intended for publication or distribution in the United States, Canada,…
MaaT PharmaFebruary 17, 2023
